Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - trametinib - melanom - antineoplastiske midler - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. ikke-småcellet lungekræft (nsclc)trametinib i kombination med dabrafenib er indiceret til behandling af voksne patienter med avanceret ikke-småcellet lungekræft med en braf v600 mutation.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - dabrafenib mesilate - melanom - antineoplastiske midler - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. adjuverende behandling af melanomadabrafenib i kombination med trametinib er angivet for den adjuverende behandling af voksne patienter med stadium iii melanom med en braf v600 mutation, efter komplet resektion. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastiske midler - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

s.a.l.f. s.p.a. - ketorolactrometamol - injektionsvæske, opløsning - 30 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

hexal ag - epoetin alfa - anemia; kidney failure, chronic; cancer - antianemiske præparater - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. behandling af anæmi og til nedsættelse af transfusion hos voksne patienter, der modtager kemoterapi for massive tumorer, malignt lymfom eller myelomatose, og ved risiko for transfusion som vurderet af patientens almene status (e. hjerte-kar-status, præ-eksisterende anæmi ved start af kemoterapi).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuklidbilleddannelse - terapeutiske radioaktive lægemidler - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm generics a/s - alitretinoin - kapsler, bløde - 10 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm generics a/s - alitretinoin - kapsler, bløde - 30 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - alitretinoin - kapsler, bløde - 10 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

1a farma a/s - paroxetin - filmovertrukne tabletter - 40 mg